Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome.
Adult
Aged
Antineoplastic Agents
/ administration & dosage
Chemoradiotherapy
/ methods
Cisplatin
/ administration & dosage
Disease-Free Survival
Docetaxel
/ administration & dosage
Esophageal Neoplasms
/ pathology
Female
Fluorouracil
/ administration & dosage
Humans
Larynx
/ drug effects
Male
Middle Aged
Neoplasm Staging
Organ Sparing Treatments
/ methods
Prognosis
Treatment Outcome
5-fluorouracil
Cisplatin
Definitive chemoradiotherapy
Docetaxel
Squamous Cell Carcinoma
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
received:
31
07
2021
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Definitive chemoradiotherapy (dCRT) is widely considered as a treatment option for cervical esophageal squamous cell carcinoma (ESCC) toward preserving the larynx. We have reported favorable outcomes, including the treatment response rate and short-term survival of dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for advanced cervical ESCC. The aim of this paper was to report the subsequent progress of the study. We assessed 18 patients with advanced (clinical stage II-IV, including T4b and/or M1 lymph node) cervical ESCC at our department who received DCF-RT as the first-line treatment between December 2010 and June 2020. A total of 14 men and 4 women underwent the study regimen. The pretreatment clinical stage included stage II, stage III, stage IVA, and stage IVB cases (including 9 patients with T4b) [8 trachea and 2 thyroids] and 7 patients with the M1 lymph node. The complete response (CR) was achieved in 15 patients, stable disease in 2, and progressive disease in 1. Of 15 patients with CR, 7 experienced recurrence, and 8 had continued CR. Frequent cases of grade ≥3 adverse effects included leucopenia, neutropenia, febrile neutropenia, and pharyngeal pain. The 3-year overall survival rate, disease-free survival rate, and disease-specific survival rate were 44.2%, 47.7%, and 48.6%, respectively. DCF-RT for advanced cervical esophageal cancer could achieve a favorable prognosis with larynx preservation. Further observations are warranted to establish the long-term prognosis, late complications of radiotherapy, and the significance of salvage surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Definitive chemoradiotherapy (dCRT) is widely considered as a treatment option for cervical esophageal squamous cell carcinoma (ESCC) toward preserving the larynx. We have reported favorable outcomes, including the treatment response rate and short-term survival of dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for advanced cervical ESCC. The aim of this paper was to report the subsequent progress of the study.
METHODS
METHODS
We assessed 18 patients with advanced (clinical stage II-IV, including T4b and/or M1 lymph node) cervical ESCC at our department who received DCF-RT as the first-line treatment between December 2010 and June 2020.
RESULTS
RESULTS
A total of 14 men and 4 women underwent the study regimen. The pretreatment clinical stage included stage II, stage III, stage IVA, and stage IVB cases (including 9 patients with T4b) [8 trachea and 2 thyroids] and 7 patients with the M1 lymph node. The complete response (CR) was achieved in 15 patients, stable disease in 2, and progressive disease in 1. Of 15 patients with CR, 7 experienced recurrence, and 8 had continued CR. Frequent cases of grade ≥3 adverse effects included leucopenia, neutropenia, febrile neutropenia, and pharyngeal pain. The 3-year overall survival rate, disease-free survival rate, and disease-specific survival rate were 44.2%, 47.7%, and 48.6%, respectively.
CONCLUSION
CONCLUSIONS
DCF-RT for advanced cervical esophageal cancer could achieve a favorable prognosis with larynx preservation. Further observations are warranted to establish the long-term prognosis, late complications of radiotherapy, and the significance of salvage surgery.
Identifiants
pubmed: 35225461
doi: 10.31557/APJCP.2022.23.2.495
pmc: PMC9272611
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-499Références
Eur Arch Otorhinolaryngol. 2016 Mar;273(3):741-7
pubmed: 25716773
Dis Esophagus. 2017 Feb 1;30(2):1-8
pubmed: 27629865
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):976-984
pubmed: 27745985
Head Neck. 2017 Dec;39(12):2406-2415
pubmed: 28960561
Acta Oncol. 2006;45(8):1120-5
pubmed: 17118849
Esophagus. 2021 Jan;18(1):1-24
pubmed: 33047261
Dis Esophagus. 2018 Jul 1;31(7):
pubmed: 29346536
Radiother Oncol. 2015 Aug;116(2):257-61
pubmed: 26233590
Ann Surg Oncol. 2017 Mar;24(3):778-784
pubmed: 27714538
Esophagus. 2018 Oct;15(4):281-285
pubmed: 29948480
Oncol Lett. 2019 Mar;17(3):3432-3438
pubmed: 30867781
Dis Esophagus. 2014 Sep-Oct;27(7):678-84
pubmed: 24147973
Oncotarget. 2017 Mar 28;8(13):21852-21860
pubmed: 28423530
Arch Otolaryngol Head Neck Surg. 2000 Feb;126(2):205-8
pubmed: 10680872
Dis Esophagus. 2007;20(1):12-8
pubmed: 17227304
Dis Esophagus. 2018 May 1;31(5):
pubmed: 29294022
Anticancer Res. 2021 Apr;41(4):2141-2145
pubmed: 33813425